10-Q: MariMed Reports Q3 Loss Amid Strategic Shifts, IRS Lien

MariMed Inc. reported a significant net loss in the third quarter of 2025 despite slight revenue growth, as it navigates strategic market exits and a substantial IRS tax liability.

Summary

• Net loss for Q3 2025 was $2.94 million, a substantial increase from $0.99 million in Q3 2024.
• Total revenue for Q3 2025 slightly increased by 0.4% to $40.76 million, driven by a 10.6% rise in wholesale sales, offsetting a 3.5% decline in retail sales.
• For the nine months ended September 30, 2025, net loss widened to $9.82 million from $4.17 million in the prior year.
• Nine-month revenue decreased by 0.5% to $118.18 million, with wholesale sales up 11.3% and retail sales down 5.1%.
• Adjusted EBITDA for Q3 2025 grew by 9.8% to $5.14 million, but decreased by 7.6% to $12.43 million for the nine-month period.
• The company completed the acquisition of First State Compassion Center (FSC) in Delaware on March 1, 2025, contributing $7.1 million in revenue and $0.8 million in net income for the nine-month period.
• MariMed announced its exit from the Missouri market on October 28, 2025, expecting a $1 million loss on disposal in Q4 2025.
• An IRS lien of approximately $6 million was filed in June 2025 for a 2023 tax liability, which the company is disputing.

Sentiment

Score: 4

Explanation: The company reported a significantly increased net loss and declining gross margins, coupled with a substantial IRS tax lien, which are major negative financial indicators. While there were strategic expansions and debt repayments, these are overshadowed by the overall financial performance and tax dispute.

Positives

• Quarterly revenue saw a slight increase of 0.4% to $40.76 million for Q3 2025 compared to Q3 2024.
• Wholesale product sales increased by 10.6% in Q3 2025 and 11.3% for the nine months ended September 30, 2025, indicating strong performance in this segment.
• Adjusted EBITDA for Q3 2025 increased by 9.8% to $5.14 million, demonstrating improved operational profitability for the quarter.
• Successful acquisition of First State Compassion Center (FSC) in Delaware, which contributed $7.1 million in revenue and $0.8 million in net income for the nine months ended September 30, 2025.
• Full satisfaction of promissory notes related to the Allgreens and MedLeaf acquisitions by July and September 2025, respectively, reducing debt obligations.
• Entered into a Management Services Agreement with Standard Farms, LLC, effective September 1, 2025, to manage a cultivation and processing facility in Pennsylvania and license brands, expanding market presence.
• Regained compliance with the OTCQX minimum bid price requirement by September 5, 2025.

Negatives

• Net loss significantly widened to $2.94 million in Q3 2025 from $0.99 million in Q3 2024, and to $9.82 million for the nine months ended September 30, 2025, from $4.17 million in the prior year.
• Gross profit decreased by 2.5% in Q3 2025 and 5.2% for the nine months ended September 30, 2025, with gross margin declining from 41.3% to 40.1% (Q3) and 42.1% to 40.1% (9 months).
• Retail product sales decreased by 3.5% in Q3 2025 and 5.1% for the nine months ended September 30, 2025, primarily due to lower sales in certain Illinois and Massachusetts dispensaries.
• Other revenue declined significantly by 82.2% in Q3 2025 and 79.8% for the nine months ended September 30, 2025, due to the cessation of management fees and rental income from FSC post-acquisition.
• Cash and cash equivalents decreased to $6.60 million at September 30, 2025, from $7.28 million at December 31, 2024.
• Operating cash flow decreased to $4.27 million for the nine months ended September 30, 2025, from $7.20 million in the prior year.
• Financing activities shifted from providing $3.88 million in cash in 2024 to using $3.77 million in 2025.
• Bad debt expense for the nine months ended September 30, 2025, was $1.52 million, including a full reserve for $1.5 million due from two credit card service providers.
• Income tax provision increased significantly to $2.76 million in Q3 2025 from $0.66 million in Q3 2024, and to $6.28 million for the nine months from $3.21 million in the prior year, contributing to the net loss.

Risks

• An approximate $6 million IRS lien was filed in June 2025 for a 2023 tax liability, which the company is disputing through a Collection Due Process (CDP) Hearing. An unfavorable outcome could materially impact operations and financial position.
• Operating in the federally illegal cannabis industry subjects the company to IRC Section 280E, limiting deductible expenses to cost of goods sold and resulting in a higher effective tax rate.
• The company has significant related party dealings, including corporate office leases, procurement of supplies, and royalty payments to entities in which the CEO and COO have investment interests or ownership. The CEO also personally guarantees mortgages.
• An unresolved $2.0 million accrued liability for electrical work performed at New Bedford and Middleborough properties between 2017 and 2023, with ongoing discussions to address payment terms.
• General business risks include changes in demand, law enforcement, regulatory processes, economic environment, pricing levels, political/social/economic conditions, technology, competition, and enforcement of U.S. federal cannabis-related laws.
• The cannabis industry faces increasing incidence of litigation, including class action suits, and compliance problems reported to regulatory authorities.

Future Outlook

The company continues to focus on executing its strategic growth plan, prioritizing increasing product brand revenue through strengthening cultivation and processing, developing new products, broadening distribution in existing markets, and expanding into new markets via licenses, acquisitions, or licensing partners. It also aims to increase retail store revenue by enhancing customer experience and expanding its dispensary footprint.

Management Comments

• "We are a multi-state cannabis operator in the United States, headquartered in Norwood, Massachusetts, dedicated to improving lives every day through our high-quality products, our actions, and our values."
• "We continue to focus on executing our strategic growth plan, with priority on activities that include increasing our product brand revenue and increasing retail store revenue."
• "Based on our current expectations, we believe our current cash and future funding opportunities will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next twelve months."
• "In the opinion of management, inflation has impacted us through increased costs of ingredients, nutrients and packaging."
• "We recently negotiated with certain of our suppliers to reduce our costs for future purchases of ingredients, nutrients and packaging, all of which have increased significantly as a result of current economic conditions."

Industry Context

The company operates in the highly regulated U.S. cannabis industry, which faces federal illegality (IRC Section 280E) impacting profitability. Its strategic moves, such as the acquisition of FSC in Delaware and the MSA with TILT in Pennsylvania, reflect a trend of multi-state operators expanding their footprint in newly legalized or expanding adult-use markets. The exit from Missouri suggests a strategic re-evaluation of market viability or focus, common in a dynamic regulatory landscape. The focus on strengthening cultivation, product innovation, and distribution aligns with broader industry efforts to capture market share and improve efficiency.

Legal Proceedings

• An approximate $6 million IRS lien was filed in June 2025 for a 2023 tax liability. The company is disputing the assessment through a Collection Due Process (CDP) Hearing and pursuing resolution, including potential reduction or collection alternatives.
• MariMed Hemp, Inc. (MMH) settled a complaint for alleged preferential transfers in 2023, reducing its general unsecured claim to $15.5 million. An incremental final liquidation distribution of $50,281 was received on October 1, 2025.
• The company is subject to ongoing business risks and potential litigation or regulatory proceedings in the ordinary course of business, especially given the highly regulated cannabis industry and increasing incidence of class action suits.

Related Party Transactions

• Corporate offices are leased from an entity in which the CEO has an investment interest, with expenses of $69,000 (Q3 2025) and $213,000 (9 months 2025).
• Nutrients, lab equipment, cultivation supplies, furniture, and tools are procured from an entity owned by the COO's family, with purchases totaling $1.3 million (Q3 2025) and $4.3 million (9 months 2025).
• Royalties on Bettys Eddies product line are paid to an entity owned by the COO and CCO, totaling $154,000 (Q3 2025) and $472,000 (9 months 2025).
• Distributions from a majority-owned subsidiary to the CEO (minority equity interest holder) were $2,000 (Q3 2025) and $5,000 (9 months 2025).
• Distributions from Mari Holdings Metropolis, LLC to the CEO and COO (who purchased membership units in June 2024) were $2,500 and $7,500 respectively (Q3 2025), and $7,500 and $22,500 respectively (9 months 2025).
• Outstanding accounts payable balance of $616,000 at September 30, 2025, primarily for fixed assets purchased from a third-party company in which the CEO has a controlling interest.
• Assumed accounts payable of $35,000 to a CEO-controlled company and $21,000 to another CEO-controlled company as part of the FSC Acquisition.
• The CEO personally guarantees the company's mortgages with Bank of New England and DuQuoin State Bank.

Stakeholder Impact

• Shareholders are impacted by the significant net loss, declining gross margins, and the uncertainty surrounding the $6 million IRS tax lien. Strategic expansions and debt repayments offer some long-term potential, but short-term profitability is a concern. The conversion of Series C preferred stock to common stock increased outstanding common shares.
• Employees experienced increased headcount due to acquisitions and expanded presence, but also strategic elimination and consolidation of certain positions.
• Customers are affected by loyalty program adjustments, and the company focuses on enhancing customer experience in existing stores.
• Creditors' interests are managed through debt repayments, but the IRS lien could impact the company's ability to meet other financial obligations if unresolved unfavorably.
• Suppliers are subject to negotiations to reduce costs for ingredients, nutrients, and packaging due to inflation.

Next Steps

• Finalize the measurement of the loss on disposal for Missouri operations in Q4 2025.
• Continue disputing the approximate $6 million IRS tax liability through a Collection Due Process (CDP) Hearing.
• Standard Farms intends to produce and distribute the company's brands in Pennsylvania upon regulatory approval.
• Continue strengthening cultivation and processing capabilities.
• Develop and launch innovative new products.
• Broaden distribution network in existing markets.
• Expand distribution into new markets through new license applications, acquisitions, and/or licensing partners.
• Drive additional and higher average transactions in existing stores.
• Expand dispensary footprint in current and new markets.
• Resolve the $2.0 million accrued liability for electrical work at New Bedford and Middleborough properties.

Key Dates

Recommendation

The company presents a mixed financial picture with a significantly increased net loss and declining gross margins, which are concerning. However, it also demonstrates strategic growth through acquisitions (FSC), market expansion (Pennsylvania via TILT MSA), and successful repayment of certain acquisition-related debt. The major unresolved issue is the $6 million IRS tax lien, which introduces significant uncertainty and risk. A seasoned investor would likely hold the stock to monitor the resolution of the IRS dispute and assess whether the strategic initiatives can translate into improved profitability and cash flow in future periods, rather than making a definitive buy or sell decision at this juncture.

Keywords

MariMed Inc., cannabis, multi-state operator, SEC 10-Q, financial results, Q3 2025, wholesale cannabis, retail cannabis, Adjusted EBITDA, net loss, IRS tax lien, Delaware cannabis, Pennsylvania cannabis, Missouri market exit, FSC Acquisition, Standard Farms, cannabis regulation, 280E, related party transactions